Jang Kyoung Min, Choi Hyun Ho, Nam Taek Kyun, Park Yong Sook, Kwon Jeong Taik, Byun Jun Soo, Hwang Doyeon
Department of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Department of Neurosurgery, Kangwon National University School of Medicine, Chuncheon, Korea.
J Korean Neurosurg Soc. 2021 Mar;64(2):207-216. doi: 10.3340/jkns.2020.0154. Epub 2021 Jan 29.
Rapid dissolution of blood clots reduces vasospasm and hydrocephalus after subarachnoid hemorrhage (SAH), and locally administered fibrinolytic drugs (LAFDs) could facilitate the dissolution. However, the efficacy of LAFDs remains controversial. The aim of this meta-analysis was to determine the efficacy of LAFDs for vasospasm and hydrocephalus and in clinical outcomes.
From PubMed, EMBASE, and Cochrane database, data were extracted by two authors. Meta-analysis was performed using a random effect model. Inclusion criteria were patients who had LAFDs with urokinase-type or recombinant tissue-plasminogen activator after SAH in comparison with medically untreated patients with fibrinolytic drugs. We only included randomized controlled trials (RCTs) in this analysis. The outcomes of interest were vasospasm, hydrocephalus, mortality, and 90-day unfavorable functional outcome.
Data from eight RCTs with 550 patients were included. Pooled-analysis revealed that the LAFDs were significantly associated with lower rates of vasospasm (LAFDs group vs. control group, 26.5% vs. 39.2%; odds ratio [OR], 0.48; 95% confidence interval [CI], 0.32-0.73); hydrocephalus (LAFDs group vs. control group, 26.0% vs. 31.6%; OR, 0.54; 95% CI, 0.32-0.91); and mortality (LAFDs group vs. control group, 10.5% vs. 15.7%; OR, 0.58; 95% CI, 0.34-0.99). The proportion of 90-day unfavorable outcomes was lower in the LAFDs group (LAFDs group vs. control group, 32.7% vs. 43.5%; OR, 0.55; 95% CI, 0.37-0.80).
This meta-analysis with eight RCTs indicated that LAFDs were significantly associated with lower rates of vasospasm and hydrocephalus after SAH. Thus, LAFDs could consequently reduce mortality and improve clinical outcome after SAH.
快速溶解血凝块可减少蛛网膜下腔出血(SAH)后的血管痉挛和脑积水,局部应用纤溶药物(LAFDs)有助于溶解。然而,LAFDs的疗效仍存在争议。本荟萃分析的目的是确定LAFDs对血管痉挛、脑积水及临床结局的疗效。
从PubMed、EMBASE和Cochrane数据库中,由两位作者提取数据。采用随机效应模型进行荟萃分析。纳入标准为SAH后接受LAFDs联合尿激酶型或重组组织型纤溶酶原激活剂治疗的患者,并与未接受纤溶药物治疗的患者进行比较。本分析仅纳入随机对照试验(RCTs)。感兴趣的结局为血管痉挛、脑积水、死亡率和90天不良功能结局。
纳入了八项RCTs的550例患者的数据。汇总分析显示,LAFDs与较低的血管痉挛发生率显著相关(LAFDs组与对照组,26.5%对39.2%;比值比[OR],0.48;95%置信区间[CI],0.32 - 0.73);脑积水(LAFDs组与对照组,26.0%对31.6%;OR,0.54;95% CI,0.32 - 0.91);以及死亡率(LAFDs组与对照组,10.5%对15.7%;OR,0.58;95% CI,0.34 - 0.99)。LAFDs组90天不良结局的比例较低(LAFDs组与对照组,32.7%对43.5%;OR,0.55;95% CI,0.37 - 0.80)。
这项包含八项RCTs的荟萃分析表明,LAFDs与SAH后较低的血管痉挛和脑积水发生率显著相关。因此,LAFDs可降低SAH后的死亡率并改善临床结局。